Oviat Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.15 M
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.11 Cr
- Revenue Growth 151.81%
- Profit Growth 143.52%
- Ebitda 138.34%
- Net Worth 64.03%
- Total Assets 62.50%
About Oviat Pharmaceuticals
Oviat Pharmaceuticals Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 March 2017 (Seven years and ten months 17 days old ). Its registered office is in Singhbhum, Jharkhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹1.11 Cr.
Anita Kumari and Sandeep Mukherjee serve as directors at the Company.
Company Details
- Location
Singhbhum, Jharkhand, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U36999JH2017PTC009752
- Company No.
009752
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Mar 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jharkhand
Industry
Who are the key members and board of directors at Oviat Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anita Kumari  | Director | 14-Mar-2017 | Current |
| Sandeep Mukherjee | Director | 19-Jan-2019 | Current |
Financial Performance of Oviat Pharmaceuticals.
Oviat Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 151.81% increase. The company also saw a substantial improvement in profitability, with a 143.52% increase in profit. The company's net worth Soared by an impressive increase of 64.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oviat Pharmaceuticals?
In 2022, Oviat Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹11.05 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.61 Cr
- State Bank Of India : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Jun 2024 | Others | ₹1.75 M | Open |
| 01 Jun 2024 | State Bank Of India | ₹5.00 M | Open |
| 04 Apr 2024 | Others | ₹1.60 M | Open |
| 16 Feb 2023 | Others | ₹2.70 M | Open |
How Many Employees Work at Oviat Pharmaceuticals?
Unlock and access historical data on people associated with Oviat Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oviat Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oviat Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
